MBHB Partner Kevin Noonan a Featured Presenter at ACI’s 2nd Advanced Summit on Life Sciences Patents

MBHB partner Dr. Kevin Noonan is a featured presenter at the American Conference Institute’s 2nd Advanced Summit on Life Sciences Patents set for Feb. 23-24, 2016 in New York City.

Details for Dr. Noonan’s presentation are as follows:

Tuesday, February 23 – 9:30-10:30 a.m. ET

The Year of the Biosimilar: Refining Current Life Sciences Patent Strategies and Formulating a Multi-Faceted Approach for Innovators and Biosimilars Manufacturers

  • Analyzing which biologics may be ripe for a biosimilar including monoclonal antibodies, therapeutic proteins, and vaccines going off patent soon

  • Crafting a winning biologic patenting strategy: Devising claim drafting methods for and against biosimilars

    • Strategies to head off biosimilar development

    • Working around narrowly written biopharmaceutical patents

    • Unique challenges for process patents

    • Claiming existing biologics broadly enough to cover biosimilars

  • Analyzing how current IP case law will shape claiming and litigating biosimilars: considerations for the safe harbor, indefiniteness, and natural products

  • Determining what may constitute a “biobetter” and choosing whether to seek pure “biosimilarity” or an improved “biobetters” product or both

  • Updates on the first BPCIA cases and the opting-in/opting-out debate: Sandoz v. Amgen and Janssen v. Celltrion


About American Conference Institute

A unique organization, American Conference Institute is devoted to providing the business intelligence that senior decision-makers need to respond to challenges both here in the US, and around the world. Staffed by industry specialists, lawyers and other professionals, American Conference Institute operates as a think tank, monitoring trends and developments in all major industry sectors, the law, and public policy, with a view to providing information on the leading edge.

View complete details including registration